First results of the two confirmatory Phase III INPULSISTM trials investigating the efficacy and safety of nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF)
COPD: First Phase III results presented from the TOviTOTM trial programme for tiotropium + olodaterol fixed-dose combination (tiotropium + olodaterol FDC*)
In total 14 abstracts with key data across IPF, COPD and asthma will be presented
April 30, 2014
Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.
The first Phase III trial results to be released from the TOviTOTM programme, investigating the once-daily fixed-dose combination of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease (COPD) will also be presented. Despite available management options, many patients with COPD continue to experience symptoms which impact their quality of life, highlighting the need for new and innovative treatments.
In total 14 abstracts submitted by Boehringer Ingelheim have been accepted for presentation at ATS. The extensive data being presented highlights the company’s leadership in pioneering innovative respiratory therapies to treat life-threatening lung diseases.
“We are excited to present the first Phase III data for tiotropium + olodaterol FDC which marks another important milestone in our goal of developing innovative therapies to address the unmet medical needs in COPD,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “Leveraging our extensive heritage and expertise in the Respiratory Therapeutic Area, Boehringer Ingelheim is expanding into further chronic respiratory areas, including rare diseases where few treatment options exist. We are dedicated to our research in idiopathic pulmonary fibrosis, which is a progressive and deadly condition but still is relatively unknown. We look forward to presenting the pivotal Phase III data in San Diego.”
Boehringer Ingelheim’s abstracts in respiratory research can be accessed through the ATS website, http://conference.thoracic.org. The data will remain under embargo until the date and time that the data are presented.
For further details please visit http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/30_april_2014_respiratory.html